Candel Therapeutics rises on orphan drug tag for glioma treatment

Candel Therapeutics

30/05/2024 15:30

** Shares of Candel Therapeutics  CADL.O  up 1.19% to $8.89
    ** The therapy developer says the FDA has granted 'orphan
drug' tag to CAN-3110 for the treatment of recurrent high-grade
glioma 
    ** Glioma is a growth of cells that starts in the brain or
spinal cord, which forms tumors as it grows
     ** The "Orphan Drug" designation is granted by the FDA to
drugs or biologics intended to treat a rare disease or
condition, defined as one that affects fewer than 200,000 people
in the United States
    ** Stock up nearly 6-fold YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))